 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of pde4d catalytic domain and zardaverine complex
|
|
Structure:
|
 |
Phosphodiesterase 4d. Chain: a, b, c, d, e, f, g, h, i, j, k, l. Fragment: catalytic domain. Synonym: camp-specific 3',5'-cyclic phosphodiesterase 4d. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Hexamer (from
)
|
|
Resolution:
|
 |
|
2.90Å
|
R-factor:
|
0.245
|
R-free:
|
0.260
|
|
|
Authors:
|
 |
M.E.Lee,J.Markowitz,J.-O.Lee,H.Lee
|
Key ref:
|
 |
M.E.Lee
et al.
(2002).
Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
FEBS Lett,
530,
53-58.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
29-Aug-02
|
Release date:
|
01-Mar-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
Q08499
(PDE4D_HUMAN) -
cAMP-specific 3',5'-cyclic phosphodiesterase 4D
|
|
|
|
Seq: Struc:
|
 |
 |
 |
809 a.a.
328 a.a.*
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
PfamB domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.4.17
- 3',5'-cyclic-nucleotide phosphodiesterase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate
|
 |
 |
 |
 |
 |
Nucleoside 3',5'-cyclic phosphate
|
+
|
H(2)O
|
=
|
nucleoside 5'-phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
signal transduction
|
1 term
|
 |
|
Biochemical function
|
catalytic activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
FEBS Lett
530:53-58
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
|
|
M.E.Lee,
J.Markowitz,
J.O.Lee,
H.Lee.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Cyclic nucleotide phosphodiesterases (PDEs) regulate physiological processes by
degrading intracellular second messengers, adenosine-3',5'-cyclic phosphate or
guanosine-3',5'-cyclic phosphate. The first crystal structure of PDE4D catalytic
domain and a bound inhibitor, zardaverine, was determined. Zardaverine binds to
a highly conserved pocket that includes the catalytic metal binding site.
Zardaverine fills only a portion of the active site pocket. More selective PDE4
inhibitors including rolipram, cilomilast and roflumilast have additional
functional groups that can utilize the remaining empty space for increased
binding energy and selectivity. In the crystal structure, the catalytic domain
of PDE4D possesses an extensive dimerization interface containing residues that
are highly conserved in PDE1, 3, 4, 8 and 9. Mutations of R358D or D322R among
these interface residues prohibit dimerization of the PDE4D catalytic domain in
solution.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Fig. 2. Dialkoxyphenyl containing PDE4 inhibitors [4, 6,
15, 16, 23, 24 and 25]. IC[50] values are written in
parentheses. The dialkoxy pharmacophores are colored in red.
|
 |
Figure 4.
Fig. 4. The dimerization of wild type and mutant PDE4D
catalytic domain. A: Purified wild type and R358D mutant protein
were injected into a Superdex 200 (APbiotech) gel filtration
column. Elution volumes for molecular weight standards are
indicated. B: Glutaraldehyde-mediated cross-linking of the
purified wild type and mutant proteins was performed as
published [26]. The cross-linked proteins were separated by
SDS–PAGE and stained with Coomassie brilliant blue R-250.
Glutaraldehyde concentrations used for each lanes are, 1, 6,
11: 0%; 2, 7, 12: 0.01%; 3, 8, 13: 0.03%; 4, 9, 14: 0.1%; 5, 10,
15: 0.3%. Mutant catalytic domains of PDE4D were cloned into the
pAcHLTA vector (BD Pharmingen) and expressed using a baculovirus
expression system. Mutant proteins could not be overexpressed in
Escherichia coli. They run in as slightly higher molecular
weight due to hexa-histidine tags. In control experiments with
wild type protein expressed in insect cells, the histidine tag
did not affect cross-linking results (data not shown).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the Federation of European Biochemical Societies:
FEBS Lett
(2002,
530,
53-58)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
R.W.Allcock,
H.Blakli,
Z.Jiang,
K.A.Johnston,
K.M.Morgan,
G.M.Rosair,
K.Iwase,
Y.Kohno,
and
D.R.Adams
(2011).
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
|
| |
Bioorg Med Chem Lett, 21,
3307-3312.
|
 |
|
|
|
|
 |
W.C.Ko,
L.H.Lin,
H.Y.Shen,
C.Y.Lai,
C.M.Chen,
and
C.H.Shih
(2011).
Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness.
|
| |
Evid Based Complement Alternat Med, 2011,
635058.
|
 |
|
|
|
|
 |
A.P.Skoumbourdis,
C.A.Leclair,
E.Stefan,
A.G.Turjanski,
W.Maguire,
S.A.Titus,
R.Huang,
D.S.Auld,
J.Inglese,
C.P.Austin,
S.W.Michnick,
M.Xia,
and
C.J.Thomas
(2009).
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
|
| |
Bioorg Med Chem Lett, 19,
3686-3692.
|
 |
|
|
|
|
 |
J.Pandit,
M.D.Forman,
K.F.Fennell,
K.S.Dillman,
and
F.S.Menniti
(2009).
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
|
| |
Proc Natl Acad Sci U S A, 106,
18225-18230.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.P.Skoumbourdis,
R.Huang,
N.Southall,
W.Leister,
V.Guo,
M.H.Cho,
J.Inglese,
M.Nirenberg,
C.P.Austin,
M.Xia,
and
C.J.Thomas
(2008).
Identification of a potent new chemotype for the selective inhibition of PDE4.
|
| |
Bioorg Med Chem Lett, 18,
1297-1303.
|
 |
|
|
|
|
 |
S.Liu,
M.N.Mansour,
K.S.Dillman,
J.R.Perez,
D.E.Danley,
P.A.Aeed,
S.P.Simons,
P.K.Lemotte,
and
F.S.Menniti
(2008).
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
|
| |
Proc Natl Acad Sci U S A, 105,
13309-13314.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Conti,
and
J.Beavo
(2007).
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
|
| |
Annu Rev Biochem, 76,
481-511.
|
 |
|
|
|
|
 |
C.Lugnier
(2006).
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
|
| |
Pharmacol Ther, 109,
366-398.
|
 |
|
|
|
|
 |
D.Wang,
and
X.Cui
(2006).
Evaluation of PDE4 inhibition for COPD.
|
| |
Int J Chron Obstruct Pulmon Dis, 1,
373-379.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
Q.Huai,
J.Cai,
R.Zoraghi,
S.H.Francis,
J.D.Corbin,
H.Robinson,
Z.Xin,
G.Lin,
and
H.Ke
(2006).
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
|
| |
J Biol Chem, 281,
21469-21479.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Huai,
Y.Sun,
H.Wang,
D.Macdonald,
R.Aspiotis,
H.Robinson,
Z.Huang,
and
H.Ke
(2006).
Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
|
| |
J Med Chem, 49,
1867-1873.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Zoraghi,
J.D.Corbin,
and
S.H.Francis
(2006).
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
|
| |
J Biol Chem, 281,
5553-5558.
|
 |
|
|
|
|
 |
S.H.Hung,
W.Zhang,
R.A.Pixley,
B.A.Jameson,
Y.C.Huang,
R.F.Colman,
and
R.W.Colman
(2006).
New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A: a role for the unique 44-amino acid insert.
|
| |
J Biol Chem, 281,
29236-29244.
|
 |
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
Y.Li,
G.F.Yang,
and
C.G.Zhan
(2006).
Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
Biophys J, 91,
1858-1867.
|
 |
|
|
|
|
 |
A.Castro,
M.J.Jerez,
C.Gil,
and
A.Martinez
(2005).
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
|
| |
Med Res Rev, 25,
229-244.
|
 |
|
|
|
|
 |
A.Tait,
A.Luppi,
A.Hatzelmann,
P.Fossa,
and
L.Mosti
(2005).
Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
|
| |
Bioorg Med Chem, 13,
1393-1402.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
Y.Chen,
H.Robinson,
and
H.Ke
(2005).
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
|
| |
J Biol Chem, 280,
30949-30955.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
P.N.Ibrahim,
S.Gillette,
and
G.Bollag
(2005).
Phosphodiesterase-4 as a potential drug target.
|
| |
Expert Opin Ther Targets, 9,
1283-1305.
|
 |
|
|
|
|
 |
M.D.Houslay,
P.Schafer,
and
K.Y.Zhang
(2005).
Keynote review: phosphodiesterase-4 as a therapeutic target.
|
| |
Drug Discov Today, 10,
1503-1519.
|
 |
|
|
|
|
 |
G.L.Card,
B.P.England,
Y.Suzuki,
D.Fong,
B.Powell,
B.Lee,
C.Luu,
M.Tabrizizad,
S.Gillette,
P.N.Ibrahim,
D.R.Artis,
G.Bollag,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
K.Y.Zhang
(2004).
Structural basis for the activity of drugs that inhibit phosphodiesterases.
|
| |
Structure, 12,
2233-2247.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
G.L.Card,
Y.Suzuki,
D.R.Artis,
D.Fong,
S.Gillette,
D.Hsieh,
J.Neiman,
B.L.West,
C.Zhang,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
G.Bollag
(2004).
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
|
| |
Mol Cell, 15,
279-286.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Huai,
H.Wang,
W.Zhang,
R.W.Colman,
H.Robinson,
and
H.Ke
(2004).
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
|
| |
Proc Natl Acad Sci U S A, 101,
9624-9629.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Huai,
Y.Liu,
S.H.Francis,
J.D.Corbin,
and
H.Ke
(2004).
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
|
| |
J Biol Chem, 279,
13095-13101.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Kunz,
T.Kloeckner,
L.O.Essen,
T.Seebeck,
and
M.Boshart
(2004).
TbPDE1, a novel class I phosphodiesterase of Trypanosoma brucei.
|
| |
Eur J Biochem, 271,
637-647.
|
 |
|
|
|
|
 |
W.Richter,
and
M.Conti
(2004).
The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases.
|
| |
J Biol Chem, 279,
30338-30348.
|
 |
|
|
|
|
 |
B.J.Sung,
K.Y.Hwang,
Y.H.Jeon,
J.I.Lee,
Y.S.Heo,
J.H.Kim,
J.Moon,
J.M.Yoon,
Y.L.Hyun,
E.Kim,
S.J.Eum,
S.Y.Park,
J.O.Lee,
T.G.Lee,
S.Ro,
and
J.M.Cho
(2003).
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
|
| |
Nature, 425,
98.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Huai,
H.Wang,
Y.Sun,
H.Y.Kim,
Y.Liu,
and
H.Ke
(2003).
Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
|
| |
Structure, 11,
865-873.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Yoshimura,
I.Sagami,
Y.Sasakura,
and
T.Shimizu
(2003).
Relationships between heme incorporation, tetramer formation, and catalysis of a heme-regulated phosphodiesterase from Escherichia coli: a study of deletion and site-directed mutants.
|
| |
J Biol Chem, 278,
53105-53111.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|